Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Biomarin pharmaceutical inc. save search
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
Published: 2023-09-15 (Crawled : 13:30) - prnewswire.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -0.34%
H: 2.01%
C: 0.89%
voxzogo europe chmp children achondroplasia positive treat
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
europe chmp positive therapy
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults
Published: 2021-07-19 (Crawled : 17:00) - biospace.com/
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
Published: 2021-07-19 (Crawled : 15:00) - prnewswire.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published: 2021-06-25 (Crawled : 12:00) - investors.biomarin.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: 0.66%
H: 1.39%
C: 0.55%
treatment europe drop positive children growth chmp achondroplasia
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
Published: 2021-01-10 (Crawled : 00:11) - prnewswire.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -6.61%
H: 1.28%
C: -3.19%
gene therapy positive therapy results phase 3 trial trial results gene therapies
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.